Literature DB >> 15358567

Dermatological manifestations of Lyme borreliosis.

Robert R Mullegger1.   

Abstract

Lyme borreliosis is a multisystem infectious disease caused by the tick-transmitted spirochete Borrelia burgdorferi sensu lato. About 80% of all Lyme borreliosis cases represent skin manifestations (dermatoborrelioses). The three characteristic dermatoborrelioses are erythema migrans, borrelial lymphocytoma, and acrodermatitis chronica atrophicans, which occur in different stages of the disease. Erythema migrans is the hallmark of early Lyme borreliosis, whereas acrodermatitis chronica atrophicans is the characteristic manifestation of late Lyme borreliosis. Several spirochetal factors (e.g. infection with different genospecies, co-infection with other tick-transmitted pathogens) as well as host factors (e.g. cytokine patterns at the site of infection) influence the course of the disease. Diagnosis in the early stage of Lyme borreliosis relies on the clinical picture, whereas serological, molecular, microbiological, and histopathological findings are important adjuncts in the diagnosis of later stages of the infection. Antibiotic treatment is necessary for all stages and manifestations of Lyme borreliosis. Doxycycline is the antibiotic of choice for most patients with dermatoborrelioses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15358567

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  16 in total

1.  The laboratory diagnosis of Lyme borreliosis: Guidelines from the Canadian Public Health Laboratory Network.

Authors: 
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-03       Impact factor: 2.471

2.  Borrelia burgdorferi Infections in the United States.

Authors:  Warren R Heymann; Dana L Ellis
Journal:  J Clin Aesthet Dermatol       Date:  2012-08

Review 3.  Lyme borreliosis.

Authors:  Allen C Steere; Franc Strle; Gary P Wormser; Linden T Hu; John A Branda; Joppe W R Hovius; Xin Li; Paul S Mead
Journal:  Nat Rev Dis Primers       Date:  2016-12-15       Impact factor: 52.329

4.  Evaluation of skin thickness lesions in patients with Lyme disease measured by modified Rodnan total skin score.

Authors:  A Moniuszko; E Gińdzieńska-Sieśkiewicz; S A Pancewicz; P Czupryna; J Zajkowska; S Sierakowski
Journal:  Rheumatol Int       Date:  2011-09-30       Impact factor: 2.631

5.  [Lymphocytoma cutis benigna. Case report of a 9 year old boy].

Authors:  A Steiner; K Stehr; W Rösch
Journal:  Urologe A       Date:  2007-02       Impact factor: 0.639

6.  Solitary erythema migrans in children: comparison of treatment with clarithromycin and amoxicillin.

Authors:  Tea Nizič; Eva Velikanje; Eva Ružić-Sabljić; Maja Arnež
Journal:  Wien Klin Wochenschr       Date:  2012-07-04       Impact factor: 1.704

Review 7.  Borrelial lymphocytoma.

Authors:  Vera Maraspin; Franc Strle
Journal:  Wien Klin Wochenschr       Date:  2022-08-09       Impact factor: 2.275

8.  Tick-specific borrelial antigens appear to be upregulated in American but not European patients with Lyme arthritis, a late manifestation of Lyme borreliosis.

Authors:  Xin Li; Klemen Strle; Peng Wang; David I Acosta; Gail A McHugh; Nikhil Sikand; Franc Strle; Allen C Steere
Journal:  J Infect Dis       Date:  2013-06-12       Impact factor: 5.226

9.  A Next-Generation Sequencing-Based Molecular Approach to Characterize a Tick Vector in Lyme Disease.

Authors:  Anil K Madugundu; Babylakshmi Muthusamy; Sreelakshmi K Sreenivasamurthy; Chandra Bhavani; Jyoti Sharma; Bankatesh Kumar; Krishna R Murthy; Raju Ravikumar; Akhilesh Pandey
Journal:  OMICS       Date:  2018-08

10.  Chemokine signatures in the skin disorders of Lyme borreliosis in Europe: predominance of CXCL9 and CXCL10 in erythema migrans and acrodermatitis and CXCL13 in lymphocytoma.

Authors:  Robert R Müllegger; Terry K Means; Junghee J Shin; Marshall Lee; Kathryn L Jones; Lisa J Glickstein; Andrew D Luster; Allen C Steere
Journal:  Infect Immun       Date:  2007-07-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.